As an indirect line of support for this concern, thrombocytopenia as dose-limiting toxicity as well as transient leucopenia have been observed in the first clinical trial combining a mild myelosuppressive standard chemotherapeutic regimen with Bcl-2 AS oligonucleotides in melanoma (Jansen et al, 2000). The gene discussed is BCL2; the disease is Thrombocytopenia.